Filter News

Immunomedics, Inc. To Present At The 22nd Annual JP Morgan Healthcare Conference

Published: Jan 07, 2004

MORRIS PLAINS, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Immunomedics, Inc. today announced that Cynthia L. Sullivan, President and Chief Executive Officer, will present at the JP Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2004, at 12:30 p.m. PST (3:30 p.m. EST).

The presentation will be webcast live and will be available in the investor relations section of the Company's website at http://www.immunomedics.com/. An archived version of the presentation will also be available through the Company's website for a limited time following the conference.

Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and other serious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and other sites of disease. Immunomedics has nine therapeutic product candidates in clinical or near clinical development and has two marketed diagnostic imaging products. The most advanced therapeutic product candidates are LymphoCide(R) (epratuzumab), for which certain Phase II clinical trials for the treatment of non-Hodgkin's lymphoma have already been completed, and CEA-Cide(R) (labetuzumab), which is in Phase I/II clinical trials for the treatment of certain solid tumors.

This release, in addition to historical information, contains forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing and other sources of capital, as well as the risks discussed in the Company's Annual Report on Form 10-K for the year June 30, 2003.

Contact:

Rebecca A. Kinner, Investor Relations (973)-605-8200

Immunomedics, Inc.

CONTACT: Rebecca A. Kinner, Investor Relations of Immunomedics, Inc.,+1-973-605-8200

Back to news